Form 4: OmniAb Director Steven Love Reports Equity Grants and RSU Vesting in Latest SEC Filing

OmniAb, Inc. Director Steven Love has reported the vesting of Restricted Stock Units and the acquisition of new equity awards, including additional RSUs and stock options, according to a recent SEC Form 4 filing.

Summary

• On June 17, 2025, Steven Love, a Director of OmniAb, Inc. (OABI), reported changes in his beneficial ownership of company securities.
• 20,000 Restricted Stock Units (RSUs) granted on June 18, 2024, vested and were converted into 20,000 shares of OmniAb Common Stock.
• Following this conversion, Steven Love's direct beneficial ownership of Common Stock increased to 58,333 shares.
• Additionally, Mr. Love was granted 20,000 new Restricted Stock Units (RSUs), bringing his total direct beneficial ownership of RSUs to 46,667.
• He also received a grant of 40,000 Stock Options, with an exercise price of $1.7 per share and an expiration date of June 17, 2035.
• The newly granted RSUs and Stock Options are set to vest in full on the earlier of the next annual meeting of the Company's stockholders following the grant date or the first anniversary of the grant date.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting person due to the acquisition of new equity and vesting of existing awards, which increases their stake and aligns their interests with the company's future performance. For the company, it's a neutral event as it represents standard compensation practices.

Positives

• Steven Love, a Director, received new equity grants (20,000 RSUs and 40,000 Stock Options), indicating continued alignment of his interests with shareholders.
• The vesting of 20,000 RSUs into common stock increases the director's direct ownership in the company, demonstrating commitment.

Future Outlook

The document indicates that the newly granted Restricted Stock Units and Stock Options will vest in full on the earlier of the next annual meeting of the Company's stockholders following the grant date or the first anniversary of the grant date, aligning future incentives with company performance.

Industry Context

This Form 4 filing details routine insider equity transactions for a director at OmniAb, Inc., a biotechnology company. Such grants are common practice in the industry to incentivize and retain key personnel, aligning their financial interests with the long-term performance of the company.

Related Party Transactions

• The reported transactions are related party transactions as they involve equity awards granted by OmniAb, Inc. to Steven Love, a director of the company.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholder value creation, as the value of the awards is tied to the company's stock performance. Dilution from new equity grants is minimal and expected as part of compensation plans.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The newly granted Restricted Stock Units and Stock Options are expected to vest on the earlier of the next annual meeting of OmniAb's stockholders or the first anniversary of the grant date (June 17, 2025).

Key Dates

Keywords

OmniAb, OABI, SEC Form 4, Insider Transaction, Steven Love, Director, Restricted Stock Units, RSU, Stock Options, Equity Grant, Beneficial Ownership, Vesting